title: Cost-effectiveness of reduced follow-up in malignant melanoma.
abstract: BACKGROUND
  Considerable variability exists in the extent and frequency of follow- up examinations for melanoma patients between different countries, generating significantly different total costs and uncertain clinical benefits.
  
  
  METHODS
  We have analyzed the follow-up of melanoma patients under clinical and economic aspects based on the latest recommendations of the American Joint Committee on Cancer (AJCC) and the German Dermatologic Society (DDG) in the Düsseldorf cohort of 526 patients (stage IIII) during a 5-year follow-up period. Outcome measures were frequency of metastasis detection, most effective detection method, costs per detected metastasis and cost per quality-adjusted life year.
  
  
  RESULTS
  Structured follow-up detected 17 recurrences in stages I-III. Physical examination and lymph node ultrasound were the only cost-effective methods at all stages, while laboratory studies were generally not cost-effective. The implementation of a reduced, yet medically adequate follow-up reducing chest X-rays, abdominal ultrasound examinations and eliminating blood tests in early stages yielded savings of more than 100,000 euro (120,000 $) annually at a tertiary care university hospital.
  
  
  CONCLUSIONS
  The implementation of a reduced follow-up for melanoma patients seems not only medically justified but also economically required without adversely affecting patient outcome.
authors.affiliation: Department of Dermatology, Heinrich-Heine-University, Düsseldorf, Germany. ulrich.hengge@uni-duesseldorf.de
authors.forename: Ulrich R
authors.initials: UR
authors.lastname: Hengge
authors.forename: Andrea
authors.initials: A
authors.lastname: Wallerand
authors.forename: Andreas
authors.initials: A
authors.lastname: Stutzki
authors.forename: Norbert
authors.initials: N
authors.lastname: Kockel
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D003362:Cost-Benefit Analysis / Q000191:economics / Q000706:statistics & numerical data; D005260:Female; D005858:Germany / Q000453:epidemiology; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000191:economics / Q000706:statistics & numerical data; D008545:Melanoma / Q000175:diagnosis* / Q000191:economics* / Q000453:epidemiology; D008875:Middle Aged; D015995:Prevalence; D018570:Risk Assessment; D012307:Risk Factors; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000191:economics* / Q000453:epidemiology; D019564:Unnecessary Procedures / Q000191:economics* / Q000706:statistics & numerical data*